Investment Thesis
ImmuCell demonstrates exceptional financial health with 45% gross margins, 19% operating margins, and strong free cash flow conversion (32.8% FCF margin), supported by conservative leverage (0.30x D/E) and fortress-like liquidity (4.82x current ratio). However, modest revenue growth of 4.3% YoY and low capital returns (6.7% ROE, 4.4% ROA) limit upside potential, suggesting a stable, profitable business lacking significant growth momentum.
Strengths
- Exceptional profitability margins (45% gross, 19% operating, 18.7% net) indicating pricing power and operational efficiency
- Outstanding balance sheet with 4.82x current ratio and 0.30x debt-to-equity providing substantial financial flexibility
- Strong free cash flow generation ($3.4M FCF, 32.8% FCF margin) with minimal capital intensity ($177.2K CapEx)
Risks
- Anemic revenue growth of 4.3% YoY is concerning for a diagnostic/biotech company needing scale
- Low return on equity (6.7%) and return on assets (4.4%) suggest inefficient capital deployment or underutilization of asset base
- Small absolute revenue base ($10.4M) limits ability to fund R&D, market expansion, or acquisitions necessary for competitive positioning
Key Metrics to Watch
- Revenue growth acceleration and year-over-year trends in top-line
- Free cash flow sustainability and capital allocation decisions
- Return on equity and asset efficiency improvements
Financial Metrics
Revenue
10.4M
Net Income
1.9M
EPS (Diluted)
$0.21
Free Cash Flow
3.4M
Total Assets
44.1M
Cash
6.8M
Profitability Ratios
Gross Margin
45.0%
Operating Margin
19.0%
Net Margin
18.7%
ROE
6.7%
ROA
4.4%
FCF Margin
32.8%
Balance Sheet & Liquidity
Current Ratio
4.82x
Quick Ratio
2.60x
Debt/Equity
0.30x
Debt/Assets
33.9%
Interest Coverage
4.55x
Long-term Debt
8.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:29:56.896555 |
Data as of: 2026-03-31 |
Powered by Claude AI